Rigel Pharmaceuticals Inc...

NASDAQ: RIGL · Real-Time Price · USD
39.55
1.66 (4.38%)
At close: Aug 15, 2025, 3:59 PM
40.00
1.14%
After-hours: Aug 15, 2025, 06:37 PM EDT

Rigel Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
101.69M 53.33M 57.6M 55.31M 36.84M 29.53M 35.79M 28.13M 26.89M 26.07M 7.75M 22.41M 29.82M 16.73M 20.41M 21.54M 26.27M 81.02M
Cost of Revenue
4.5M 4.41M 5.79M 8.03M 2.81M 2.02M 3.79M 1.27M 1.07M 977K 342K 250K 1.04M 121K 487K 151K 129K 316K
Gross Profit
97.18M 48.92M 51.81M 47.28M 34.03M 27.51M 32M 26.87M 25.81M 25.09M 33.57M 22.16M 28.78M 16.61M 19.92M 21.39M 26.14M 80.7M
Operating Income
61.1M 12.77M 16.66M 14.06M 447K -6.97M 1.97M -4.46M -5.27M -12.72M 2.08M -18.4M -12.96M -26.26M -21.42M -19.79M -13.05M 41.76M
Interest Income
753K 591K 522K 425K 552K 593K 678K 672K 529K 393K 429K 192K 42K 21K 16K 14K 16K 1K
Pretax Income
59.98M 11.51M 15.22M 12.42M -1.03M -8.25M 737K -5.69M -6.6M -13.54M 1.4M -19.04M -13.49M -27.45M -22.7M -21.09M -14.79M 41.27M
Net Income
59.61M 11.45M 14.34M 12.42M -1.03M -8.25M 737K -5.69M -6.6M -13.54M 1.4M -19.67M -13.49M -27.45M -22.64M -20.95M -13.82M 39.5M
Selling & General & Admin
29.26M 27.71M 29.52M 27.04M 28.05M 28.45M 26.85M 24.86M 26.31M 27.73M 32.17M 25.9M 26.98M 27.4M 24.52M 22.88M 22.38M 22.12M
Research & Development
6.82M 8.44M 5.63M 6.18M 5.54M 6.03M 3.19M 6.47M 4.77M 10.09M 15.37M 14.67M 14.77M 15.47M 13.3M 18.3M 16.81M 16.83M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.32M n/a n/a n/a 3.52M n/a n/a n/a
Operating Expenses
36.08M 36.15M 35.15M 33.23M 33.59M 34.48M 30.04M 31.33M 31.08M 37.82M 48.86M 40.56M 41.75M 42.88M 37.82M 41.18M 39.19M 38.95M
Interest Expense
1.87M 1.85M 1.96M 2.06M 2.03M 1.87M 1.91M 1.9M 1.86M 1.2M 1.11M 826K 569K 1.21M 1.3M 1.32M 1.76M 485K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a 544K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
40.58M 40.56M 40.94M 41.25M 36.39M 36.5M 33.83M 32.6M 32.15M 38.8M 47.2M 40.81M 42.78M 43M 41.83M 41.33M 39.31M 39.26M
Income Tax Expense
369K 65K 881K n/a n/a n/a n/a n/a n/a n/a n/a 634K n/a n/a -60K -136K -970K 1.77M
Shares Outstanding (Basic)
17.89M 17.81M 17.65M 17.6M 17.55M 17.52M 17.45M 17.25M 17.36M 16.92M 17.29M 17.28M 17.21M 17.18M 17.11M 17.09M 17.02M 16.98M
Shares Outstanding (Diluted)
18.16M 18.17M 17.69M 17.65M 17.55M 17.52M 17.45M 17.44M 17.36M 17.36M 17.29M 17.28M 17.21M 17.18M 17.11M 17.09M 17.02M 17.61M
EPS (Basic)
3.33 0.64 0.81 0.71 -0.06 -0.47 0.04 -0.33 -0.38 -0.78 0.08 -1.1 -0.78 -1.6 -1.32 -1.23 -0.81 2.33
EPS (Diluted)
3.28 0.63 0.81 0.70 -0.06 -0.47 0.04 -0.33 -0.38 -0.8 0.08 -1.1 -0.78 -1.6 -1.3 -1.23 -0.81 2.20
EBITDA
62.46M 13.97M 17.78M 15.09M 1.06M -5.97M 2.94M -3.49M -4.44M -11.97M 2.79M -17.97M -12.69M -26M -21M -19.51M -12.77M 41.99M
EBIT
61.86M 13.36M 17.18M 14.48M 999K -6.37M 2.64M -3.79M -4.74M -12.33M 2.51M -18.21M -12.92M -26.24M -21.4M -19.77M -13.03M 41.76M
Depreciation & Amortization
607K 604K 604K 611K 613K 400K 293K 300K 296K 357K 284K 240K 237K 237K 404K 261K 258K 239K